Market Overview

Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study

Share:
Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study

Eli Lilly And Co (NYSE: LLY) reported positive data for its plaque psoriasis drug Tuesday in a head-to-head comparison study with Johnson & Johnson (NYSE: JNJ)'s Janssen unit's Tremfya.

What Happened

Lilly said Tuesday ahead of the market open that Talz, a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine, met the primary and all major secondary endpoints up to 12 weeks in the Phase 4 IXORA-R study.

Taltz has been approved for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and also for adults with psoriatic arthritis.

The IXORA-R trial evaluated the efficacy and safety of Taltz versus Janssen's Tremfya — an IL-23/P19 inhibitor — in people living with moderate to severe plaque psoriasis, with a Psoriasis Area Severity Index, or PASI, 100 score as the primary endpoint.

Taltz showed superiority to Tremfya in the proportion of patients achieving complete skin clearance, according to Lilly.

The company said Taltz also met all major secondary endpoints up to week 12.

Why It's Important

Dermatologists aim for complete clear skin and rapid symptom relief.

The head-to-head data provides information for individual treatment goal discussions between health care providers and their patients, Andrew Blauvelt, M.D., a dermatologist and president of the Oregon Medical Research Center, said in a statement. 

Lilly said it plans to submit detailed data from the study for presentations at future scientific meetings and peer-reviewed journals.

Lilly shares were up 1.6% at $115.47 at the time of publication Tuesday. 

Related Links:

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

Posted-In: News Health Care Trading Ideas General Best of Benzinga

 

Related Articles (JNJ + LLY)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Jim Cramer Shares His Thoughts On Delta Air Lines, Okta And More

Pax Labs Hires Headset As Main VMI Provider